The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is
The COMP at the EMA has issued a positive opinion for orphan designation of CAN04 for treatment of pancreatic cancer. The opinion is forwarded to the
The EMA orphan designation is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions that are rare and affect not more than five in 10,000 people in the EU. For a therapy to qualify for orphan designation in the EU, one of several requirements is that, unless no satisfactory method of treatment of the condition concerned has been authorized, the therapy must be of significant benefit to those affected by the condition. Therapies that meet the EMA's orphan designation criteria qualify for several incentives, including 10 years of market exclusivity, protocol assistance, and potentially reduced fees for regulatory activities. More information is available at www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation-research-development.
CAN04 is currently evaluated in two ongoing clinical trials for treatment of PDAC. In parallel with the CANFOUR study, CAN04 is also investigated in combination with FOLFIRINOX as first line therapy in patients with metastatic PDAC in the phase Ib trial CAPAFOUR. Interim efficacy data from 33 PDAC patients in CANFOUR show that the CAN04 combination therapy results in durable responses or pseudoprogression, leading to both prolonged progression-free survival and median overall survival compared to historical control data. Preparations are ongoing for late-stage development in PDAC, to be initiated during 2022.
"Orphan designation provides a large number of opportunities for nadunolimab. We intend to take advantage of those in our strong commitment to advance the development towards new treatment alternatives in pancreatic cancer.", said Göran Forsberg, CEO of
For further information, please contact:
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This is information that
About
About nadunolimab (CAN04)
The antibody CAN04 binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1- and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in multiple ongoing clinical trials. In the phase I/IIa-study CANFOUR, first line combination therapy is investigated with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) and patients with NSCLC (cisplatin/gemcitabine) (NCT03267316). Positive interim data for the combination therapies show durable responses or pseudoprogression in patients with PDAC, resulting in median iPFS of 7.8 months and median survival of 12.6 months. Stronger efficacy was also observed in NSCLC patients with median PFS of 7.2 months. A response rate of 53% was observed in non-squamous NSCLC patients, with even higher responses in patients previously treated with pembrolizumab. These results show stronger efficacy than expected from chemotherapy alone. CAN04 is investigated with chemotherapy also in the phase I study CAPAFOUR, with the FOLFIRINOX regimen for first line treatment of metastatic PDAC (NCT04990037), and in two further clinical studies, CESTAFOUR and TRIFOUR, in additional forms of cancer, including biliary tact cancer, colorectal cancer and triple negative breast cancer. CAN04 is also evaluated with the immune checkpoint inhibitor pembrolizumab, with or without chemotherapy, in the phase I study CIRIFOUR (NCT04452214).
https://news.cision.com/cantargia-ab/r/cantargia-receives-positive-ema-opinion-for-orphan-designation-of-nadunolimab-for-treatment-of-pancr,c3432220
https://mb.cision.com/Main/7470/3432220/1480424.pdf
(c) 2021 Cision. All rights reserved., source